↓ Skip to main content

Drug Repurposing for the Treatment of Acute Myeloid Leukemia

Overview of attention for article published in Frontiers in Medicine, November 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter
3 X users
patent
1 patent
facebook
2 Facebook pages

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
107 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Drug Repurposing for the Treatment of Acute Myeloid Leukemia
Published in
Frontiers in Medicine, November 2017
DOI 10.3389/fmed.2017.00211
Pubmed ID
Authors

Vibeke Andresen, Bjørn T. Gjertsen

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the accumulation of immature myeloid progenitor cells in the bone marrow, compromising of normal blood cell production and ultimately resulting in bone marrow failure. With a 20% overall survival rate at 5 years and 50% in the 18- to 65-year-old age group, new medicines are needed. It is proposed that development of repurposed drugs may be a part of the new therapy needed. AML is subdivided into recurrent molecular entities based on molecular genetics increasingly accessible for precision medicine. Novel therapy developments form a basis for novel multimodality therapy and include liposomal daunorubicin/cytarabine, broad or FLT3-specific tyrosine kinase inhibitors, Bcl-2 family inhibitors, selective inhibitors of nuclear export, metabolic inhibitors, and demethylating agents. The use of non-transplant immunotherapy is in early development in AML with the exceptional re-approval of a toxin-conjugated anti-CD33. However, the full potential of small molecule inhibitors and modalities like immunological checkpoint inhibitors, immunostimulatory small molecules, and CAR-T cell therapy is unknown. Some novel therapeutics will certainly benefit AML patient subgroups; however, due to high cost, more affordable alternatives are needed globally. Also the heterogeneity of AML will likely demand a broader repertoire of therapeutic molecules. Drug repurposing or repositioning represent a source for potential therapeutics with well-known toxicity profiles and reasonable prices. This implies that biomarkers of response need to accompany the development of antileukemic therapies for sharply defined patient subgroups. We will illustrate repurposing in AML with selected examples and discuss some experimental and regulatory limitations that may obstruct this development.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 107 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 23 21%
Student > Ph. D. Student 14 13%
Student > Bachelor 14 13%
Researcher 11 10%
Other 7 7%
Other 17 16%
Unknown 21 20%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 30 28%
Medicine and Dentistry 18 17%
Pharmacology, Toxicology and Pharmaceutical Science 11 10%
Agricultural and Biological Sciences 7 7%
Chemistry 4 4%
Other 8 7%
Unknown 29 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 April 2022.
All research outputs
#6,282,360
of 23,577,654 outputs
Outputs from Frontiers in Medicine
#1,440
of 6,086 outputs
Outputs of similar age
#120,972
of 441,227 outputs
Outputs of similar age from Frontiers in Medicine
#19
of 71 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 6,086 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.6. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,227 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.